首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa.
【2h】

Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa.

机译:5-羟色胺3受体拮抗剂ICS 205-930对原发性神经性厌食症患者的胃排空和肛门运动功能缺乏系统性影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. The 5-hydroxytryptamine 3 receptor antagonist, ICS 205-930, has been reported to have potent effects on gastric smooth muscle and to enhance gastric emptying in animals, but findings in man have been inconsistent. 2. This study investigated the effects of ICS 205-930 on gastric emptying of an isotopically labelled semisolid 1168 kJ meal and on antral contractility in patients with primary anorexia nervosa, a condition frequently associated with impaired gastric motor function. 3. Thirteen female patients (age 18-39 years, median 22 years; percentage of ideal body weight 52-90%, median 66%) participated each in two studies, in which 0.15-0.18 mg kg-1 ICS 205-930 or placebo were infused i.v. in crossover, double-blind fashion. Gastric emptying and antral contractility were recorded scintigraphically for 50 min. 4. ICS 205-930 did not affect gastric emptying: the mean percentage of meal remaining in the stomach after 50 min (69.6% +/- 3.2 s.e. mean) was nearly identical to that after placebo (70.7 +/- 3.3%). 5. Amplitude, frequency and propagation velocity of antral contractions differed only little after ICS 205-930 and placebo, respectively. 6. The results show that ICS 205-930 has no effect on the impaired gastric motor activity in primary anorexia nervosa and thus provide further evidence that the compound does not have prominent prokinetic effects in man.
机译:1.据报道,5-羟色胺3受体拮抗剂ICS 205-930对动物的胃平滑肌具有有效作用,并能增强动物的胃排空,但在人体内的发现并不一致。 2.这项研究调查了ICS 205-930对同位素标记的半固体1168 kJ膳食的胃排空以及对原发性神经性厌食症(经常与胃运动功能受损有关的患者)的胃窦收缩性的影响。 3. 13名女性患者(年龄18-39岁,中位数22岁;理想体重百分比52-90%,中位数66%)分别参加了两项研究,其中0.15-0.18 mg kg-1 ICS 205-930或静脉注射安慰剂以交叉,双盲的方式。通过闪烁显像记录胃排空和胃窦收缩50分钟。 4. ICS 205-930不会影响胃排空:50分钟后平均留在胃中的膳食百分比(69.6%+/- 3.2 s.e.平均值)与安慰剂后的平均百分比几乎相同(70.7 +/- 3.3%)。 5.分别在ICS 205-930和安慰剂治疗后,胃窦收缩的幅度,频率和传播速度差异不大。 6.结果表明,ICS 205-930对原发性神经性厌食症的胃运动功能受损没有影响,因此进一步提供了该化合物对人没有明显的促运动作用的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号